Variation in Follow-Up after Radical Cystectomy for Bladder Cancer-An Inventory Roundtable and Literature Review
Por:
Contieri, R, Pichler, R, del Giudice, F, Marcq, G, Gallioli, A, Albisinni, S, Soria, F, d'Andrea, D, Krajewski, W, Carrion, DM, Mari, A, van Rhijn, BWG, Moschini, M, Pradere, B, Mertens, LS
Publicada:
1 may 2024
Resumen:
Background: Follow-up after radical cystectomy (RC) for bladder cancer can be divided into oncological and functional surveillance. It remains unclear how follow-up after RC should ideally be scheduled. The aim of this report was to gain insight into the organization of follow-up after RC in Europe, for which we conducted a roundtable inventory within the EAU Young Academic Urologists Urothelial Cancer working group. Methods: An inventory semi-structured survey was performed among urologists of the EAU Young Academic Urologists Urothelial Cancer working group to describe the organization of follow-up. The surveys were analyzed using a deductive approach. Similarities and differences in follow-up after RC for bladder cancer were described. Results: The survey included 11 urologists from six different European countries. An institutional follow-up scheme was used by six (55%); three (27%) used a national or international guideline, and two (18%) indicated that there was no defined follow-up scheme. Major divergent aspects included the time points of follow-up, the frequency, and the end of follow-up. Six centers (55%) adopted a risk-adapted follow-up approach tailored to (varying) patient and tumor characteristics. Laboratory tests and CT scans were used in all cases; however, the intensity and frequency varied. Functional follow-up overlapped with oncological follow-up in terms of frequency and duration. Patient-reported outcome measures were only used by two (18%) urologists. Conclusions: Substantial variability exists across European centers regarding the follow-up after RC for bladder cancer. This highlights the need for an international analysis focusing on its organization and content as well as on opportunities to improve patients' needs during follow-up after RC.
Filiaciones:
Contieri, R:
Netherlands Canc Inst, Dept Urol, NL-1066 CX Amsterdam, Netherlands
Humanitas Univ, Dept Biomed Sci, I-20090 Milan, Italy
Pichler, R:
Med Univ Innsbruck, Comprehens Canc Ctr Innsbruck, Dept Urol, A-6020 Innsbruck, Austria
del Giudice, F:
Sapienza Univ Rome, Policlin Umberto Hosp 1, Dept Maternal Infant & Urol Sci, I-00185 Rome, Italy
Marcq, G:
CHU Lille, Claude Huriez Hosp, Urol Dept, F-59000 Lille, France
Gallioli, A:
Autonomous Univ Barcelona, Dept Urol, Fundacio Puigvert, Barcelona 08193, Spain
Albisinni, S:
Univ Roma Tor Vergata, Tor Vergata Univ Hosp, Dept Surg Sci, Urol Unit, I-00133 Rome, Italy
Soria, F:
Torino Sch Med, Dept Surg Sci, Div Urol, AOU Citta Salute & Sci Torino, I-10126 Turin, Italy
d'Andrea, D:
Med Univ Vienna, Dept Urol, A-1090 Vienna, Austria
Krajewski, W:
Wroclaw Med Univ, Dept Minimally Invas Robot Urol, Ctr Excellence Urol, PL-50556 Wroclaw, Poland
Carrion, DM:
Torrejon Univ Hosp, Dept Urol, Madrid 28850, Spain
Mari, A:
Univ Florence, Careggi Hosp, Dept Expt & Clin Med, Oncol Minimally Invas Urol & Androl Unit, I-50121 Florence, Italy
van Rhijn, BWG:
Netherlands Canc Inst, Dept Urol, NL-1066 CX Amsterdam, Netherlands
European Assoc Urol, Nonmuscle Invas Bladder Canc Guidelines Panel, NL-6803 AA Arnhem, Netherlands
Moschini, M:
Univ Vita Salute San Raffaele, IRCCS San Raffaele Hosp, Dept Urol, I-20132 Milan, Italy
Pradere, B:
Med Univ Vienna, Comprehens Canc Ctr, Dept Urol, A-1090 Vienna, Austria
La Croix Du Sud Hosp, Dept Urol UROSUD, F-31130 Quint Fonsegrives, France
Mertens, LS:
Netherlands Canc Inst, Dept Urol, NL-1066 CX Amsterdam, Netherlands
gold, Green Published
|